아시아 태평양 운동실조증 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 운동실조증 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 363
  • 그림 수: 48

>아시아 태평양 실조증 시장, 유형별(척추소뇌성 실조증, 운동실조-모세혈관확장증, 간헐성 실조증 및 기타(다발계통위축증(MSA))), 제품( 치료 및 진단), 투여 형태(고체, 액체 및 기타), 투여 경로(경구, 비경구 및 기타), 환자 유형(성인, 소아 및 노인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 업계 동향 및 2029년까지의 예측.

아시아 태평양 운동실조증 시장

아시아 태평양 시장 분석 및 통찰력 

운동 실조증의 유병률이 증가함에 따라 시장 수요가 증가했습니다. 더 나은 건강 서비스를 위한 의료비 지출 증가도 시장 성장에 기여합니다. 이 중요한 기간 동안 주요 시장 참여자들은 제품 출시와 제품 승인에 매우 집중하고 있습니다. 또한 정부와 규제 기관은 급증하는 부상으로 인해 제품 승인을 통해 시장 참여자들을 지원하고 있습니다.

아시아 태평양 운동실조증 시장

아시아 태평양 운동실조증 시장

아시아 태평양 운동 실조증 시장은 시장 참여자의 증가와 첨단 제품의 가용성으로 인해 예측 연도에 성장하고 있습니다. 이와 함께 제조업체는 시장에 새로운 제품을 출시하기 위한 R&D 활동에 참여하고 있습니다. 운동 실조증 치료 분야의 연구 증가와 알코올 및 약물 사용 증가는 시장 성장을 더욱 촉진할 것으로 예상됩니다. 그러나 일부 개발도상국에서 질병 진단의 어려움과 유전자 검사 시설의 부족은 예측 기간 동안 아시아 태평양 운동 실조증 시장의 성장을 방해할 수 있습니다.

증가하는 의료비 지출과 시장 참여자들의 전략적 이니셔티브는 시장에 치료를 개선할 기회를 제공할 수 있습니다. 그러나 다양한 회사의 약물 및 제품 승인과 제품 리콜과 관련된 몇 가지 엄격한 규칙과 규정이 시장 성장에 도전할 것으로 예상됩니다.

아시아 태평양 운동실조증 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 7.8%의 CAGR로 성장하고 있으며 2021년 4,443.95천 달러에서 2029년까지 7,734.86천 달러에 도달할 것으로 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

수익은 천 달러, 가격은 달러로 표시됨

다루는 세그먼트

유형별( 척추소뇌성 실조증, 실조증-모세혈관확장증, 발작성 실조증 및 기타(다발계통위축증(MSA))), 제품별( 치료 및 진단), 투여 형태(고형, 액체 및 기타), 투여 경로(경구, 비경구 및 기타), 환자 유형(성인, 소아 및 노인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타)

적용 국가

China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of the Asia-Pacific

Market Players Covered

Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Reata Pharmaceuticals, Inc., Biohaven Pharmaceuticals, among others

Market Definition

Ataxia is a term for a group of disorders that affect coordination, balance, and speech. Anybody part can be affected, but people with ataxia often have difficulties with balance, walking, speaking, swallowing, and tasks requiring a high degree of control, such as writing, eating, and vision. The exact symptoms and their severity vary depending on the type of ataxia a person has.

Ataxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. This damage can be part of an underlying condition such as MS (multiple sclerosis) or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. Hereditary ataxia is caused by a faulty gene passed on by family members who may or may not be affected.

Asia-Pacific Ataxia Market Dynamics

Drivers

  • Increasing prevalence and incidence of ataxia

Ataxia is the term for neurological diseases related to the nervous system that affects movement and coordination. People with ataxia often have trouble with balance, coordination, swallowing, and speech. Ataxia usually develops due to damage to a part of the brain, which is the cerebellum that coordinates movement. It is a rare disease, and its incidences are very prevalent globally. The disease has been widely recognized as a major clinical problem worldwide, carrying high morbidity and mortality burden. Hence, increasing prevalence and incident rates of ataxia affecting different age groups drive the Asia-Pacific ataxia market.

  • Rapid research in the field of ataxia therapeutics

There is an enormous range of risk factors being reported for ataxia. Hence, to reduce the risk factors and symptoms associated with it, various research is going on in the field of ataxia treatments. Some government funding has also been initiated to treat various types of ataxia in the market. Various rapid research in the field of ataxia therapeutics may help drive the market over the forecasted period and anticipate the major growth in the research and development for the same.

Opportunities

  • Rising healthcare expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for ataxia as the disorder has been highly prevalent in recent years

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the ataxia market in the forecast period of 2022-2029.

Restraints/Challenges

However, the difficulty in diagnosing the disease and lack of genetic testing facilities in some of the developing countries will impede the growth rate of the ataxia market. Additionally, stringent rules and regulations will further challenge the forecast period's market.

This Asia-Pacific ataxia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific ataxia market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

Post-COVID-19 Impact on Asia-Pacific Ataxia Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence, various treatment drugs have widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

  • In November 2022, Pfizer Inc. announced that the company had completed its acquisition of Arena Pharmaceuticals. It is a clinical-stage company developing innovative potential therapies to treat several immuno-inflammatory diseases. This has helped the company to increase its product portfolio with this acquisition

Asia-Pacific Ataxia Market Scope

Asia-Pacific ataxia market is segmented into type, product, dosage form, route of administration, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Spinocerebellar Ataxias
  • Ataxia-Telangiectasia
  • Episodic Ataxia
  • Others (Multiple System Atrophy (MSA))

아시아 태평양 지역 실조증 시장은 유형을 기준으로 척추소뇌성 실조증, 실조증-모세혈관확장증, 간헐성 실조증 및 기타(다발계통위축증(MSA))로 구분됩니다.

제품

  • 진단
  • 치료

아시아 태평양 운동실조증 시장은 제품을 기준으로 치료와 진단으로 구분됩니다.

투여 형태

  • 단단한
  • 액체
  • 기타

아시아 태평양 실조증 시장은 투여 형태를 기준으로 고체, 액체 및 기타로 구분됩니다.

투여 경로

  • 경구     
  • 비경구적
  • 기타

투여 경로를 기준으로 아시아 태평양 실조증 시장은 경구, 비경구 및 기타로 구분됩니다.

환자 유형

  • 성인
  • 어린이
  • 노인

아시아 태평양 지역 운동실조증 시장은 환자 유형을 기준으로 성인, 소아, 노인으로 구분됩니다.

최종 사용자

  • 병원
  • 클리닉
  • 홈 헬스케어
  • 기타

아시아 태평양 실조증 시장은 최종 사용자를 기준으로 병원, 진료소, 가정 건강 관리 및 기타로 구분됩니다.

유통 채널

  • 직접 입찰
  • 소매 판매
  • 기타

아시아 태평양 운동실조증 시장

유통채널 기준으로 아시아태평양 실조증 시장은 직접입찰, 소매판매, 기타로 구분된다.

아시아 태평양 운동실조증 시장 지역 분석/통찰력

아시아 태평양 운동실조증 시장을 분석하고, 국가, 유형, 제품, 투여 형태, 투여 경로, 환자 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

이 지역에서 다루는 국가 중 일부는 중국, 일본, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 아시아 태평양의 나머지 지역입니다. 중국은 시장 점유율과 시장 수익 측면에서 아시아 태평양 운동 실조증 시장을 지배할 것으로 예상되며 예측 기간 동안 지배력을 계속 유지할 것입니다. 이는 이 지역에서 운동 실조증이 널리 퍼져 있고, 신속한 연구 개발로 시장이 활성화되고 있기 때문입니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 아시아 태평양 운동실조증 시장 점유율 분석

아시아 태평양 운동 실조증 시장 경쟁 구도는 경쟁자들의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 아시아 태평양 운동 실조증 시장에 대한 회사의 초점과만 관련이 있습니다.

아시아 태평양 운동실조증 시장의 주요 기업으로는 Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Reata Pharmaceuticals, Inc., Biohaven Pharmaceuticals 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC ATAXIA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 ASIA PACIFIC ATAXIA MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA

7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS

7.1.3 RISE IN ALCOHOL AND DRUG USAGE

7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE

7.2 RESTRAINTS

7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE

7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE EXPENDITURE

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 STRINGENT RULES AND REGULATIONS

7.4.2 PRODUCT RECALL

8 ASIA PACIFIC ATAXIA MARKET, BY TYPE

8.1 OVERVIEW

8.2 SPINOCEREBELLAR ATAXIAS

8.2.1 TYPE 3

8.2.2 TYPE 2

8.2.3 TYPE 1

8.2.4 OTHERS

8.3 ATAXIA-TELANGIECTASIA

8.4 EPISODIC ATAXIA

8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))

9 ASIA PACIFIC ATAXIA MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 TREATMENT

9.2.1 PHARMACOTHERAPY

9.2.1.1 STIFFNESS/SPASTICITY

9.2.1.1.1 GABAPENTIN

9.2.1.1.2 LEVODOPA

9.2.1.1.3 OTHERS

9.2.1.2 GAIT AND TREMORS

9.2.1.2.1 VARENICLINE

9.2.1.2.2 RILUZOLE

9.2.1.2.3 AMANTADINE

9.2.1.2.4 OTHERS

9.2.1.3 ANTI-OXIDANTS

9.2.1.3.1 N‐ACETYLCYSTEINE

9.2.1.3.2 SELEGILINE

9.2.1.3.3 DEHYDROEPIANDROSTERONE

9.2.1.3.4 VITAMIN E

9.2.1.4 NON ANTI-OXIDANTS

9.2.1.4.1 ERYTHROPOIETIN

9.2.1.4.2 DEFERIPRONE

9.2.1.4.3 RESVERATROL

9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS

9.2.1.5 ANTI-ARRHYTHMIC AGENTS

9.2.1.5.1 AMIODARONE

9.2.1.5.2 PROPAFENONE

9.2.1.5.3 FLECAINIDE

9.2.1.5.4 IBUTILIDE

9.2.1.6 ANTI-CARDIAC FAILURE

9.2.1.6.1 BENAZEPRIL

9.2.1.6.2 LISINOPRIL

9.2.1.6.3 CAPTOPRIL

9.2.1.6.4 ENALAPRIL

9.2.1.6.5 FOSINOPRIL

9.2.1.6.6 MOEXIPRIL

9.2.1.6.7 OTHERS

9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS

9.2.1.7.1 BIGUANIDES (METFORMIN)

9.2.1.7.2 SULFONYLUREAS

9.2.1.7.2.1 GLIPIZIDE

9.2.1.7.2.2 GLIMEPIRIDE

9.2.1.7.2.3 GLYBURIDE

9.2.1.7.2.4 OTHERS

9.2.1.7.3 THIAZOLIDINEDIONES

9.2.1.7.4 MEGLITINIDES

9.2.2 LIFESTYLE THERAPY

9.2.2.1 PHYSICAL THERAPY

9.2.2.2 SPEECH THERAPY

9.2.2.3 PALLIATIVE CARE

9.2.2.4 OTHERS

9.2.3 SUPPORTIVE DEVICES

9.2.3.1 WALKING AIDS

9.2.3.2 WHEELCHAIRS

9.2.3.3 OTHERS

9.3 DIAGNOSTICS

9.3.1 IMAGING TEST

9.3.1.1 MRI SCAN

9.3.1.2 OTHERS

9.3.2 BLOOD TEST

9.3.3 GENETIC TESTING

10 ASIA PACIFIC ATAXIA MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 SOLID

10.2.1 TABLETS

10.2.2 CAPSULES

10.2.3 OTHERS

10.3 LIQUIDS

10.3.1 INJECTION

10.3.2 SOLUTIONS

10.3.3 OTHERS

10.4 OTHERS

11 ASIA PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.4 OTHERS

12 ASIA PACIFIC ATAXIA MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.2.1 MALE

12.2.2 FEMALE

12.3 CHILD

12.4 GERIATRIC

13 ASIA PACIFIC ATAXIA MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 ASIA PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.3.1 HOSPITAL PHARMACY

14.3.2 RETAIL SHOP

14.3.3 ONLINE PHARMACY

14.4 OTHERS

15 ASIA PACIFIC ATAXIA MARKET, BY GEOGRAPHY

15.1 ASIA-PACIFIC

15.1.1 CHINA

15.1.2 JAPAN

15.1.3 INDIA

15.1.4 SOUTH KOREA

15.1.5 AUSTRALIA

15.1.6 SINGAPORE

15.1.7 THAILAND

15.1.8 MALAYSIA

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 RESTF OF ASIA-PACIFIC

16 ASIA PACIFIC ATAXIA MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 SELECT MEDICAL CORPORATION

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 AMNEAL PHARMACEUTICALS LLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLI

18.4.5 RECENT DEVELOPMENT

18.5 UPSTREAM REHABILITATION INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 PRIORY

18.6.1 COMPANY SNAPSHOT

18.6.2 COMPANY SHARE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACORDA THERAPEUTICS, INC.

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 ADVERUM BIOTECHNOLOGIES, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 APOTEX INC.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 ATI PHYSICAL THERAPY

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 AUROBINDO PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 BANNER HEALTH

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 BIOHAVEN PHARMACEUTICALS

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 BIOVISTA

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 CIPLA INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 DESIGN THERAPEUTICS, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 INTRABIO

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

18.18 LUPIN.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 MATRIX BIOMED

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 MERCK KGAA

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENTS

18.21 REATA PHARMACEUTICALS, INC.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 RETROTOPE INC.

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 SANOFI

18.23.1 COMPANY SNAPSHOT

18.23.2 REVENUE ANALYSIS

18.23.3 PRODUCT PORTFOLIO

18.23.4 RECENT DEVELOPMENT

18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

18.25 SUTTER HEALTH

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENTS

18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 VIATRIS INC.

18.27.1 COMPANY SNAPSHOT

18.27.2 REVENUE ANALYSIS

18.27.3 PRODUCT PORTFOLIO

18.27.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1  ASIA PACIFIC ATAXIA MARKET: PIPELINE ANALYSIS

TABLE 2  ASIA PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3  ASIA PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4  ASIA PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5  ASIA PACIFIC ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6  ASIA PACIFIC EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7  ASIA PACIFIC OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8  ASIA PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 9  ASIA PACIFIC TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 10  ASIA PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 11  ASIA PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 12  ASIA PACIFIC STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 13  ASIA PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 14  ASIA PACIFIC ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 15  ASIA PACIFIC NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 16  ASIA PACIFIC ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 17  ASIA PACIFIC ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 18  ASIA PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 19  ASIA PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 20  ASIA PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 21  ASIA PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 22  ASIA PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23  ASIA PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 24  ASIA PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 25  ASIA PACIFIC ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 26  ASIA PACIFIC SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27  ASIA PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 28  ASIA PACIFIC LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29  ASIA PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 30  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31  ASIA PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 32  ASIA PACIFIC ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33  ASIA PACIFIC PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35  ASIA PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 36  ASIA PACIFIC ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37  ASIA PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 38  ASIA PACIFIC CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39  ASIA PACIFIC GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40  ASIA PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41  ASIA PACIFIC HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42  ASIA PACIFIC CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43  ASIA PACIFIC HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45  ASIA PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 46  ASIA PACIFIC DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 47  ASIA PACIFIC RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48  ASIA PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 49  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50  ASIA-PACIFIC ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 51  ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 52  ASIA-PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 53  ASIA-PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 54  ASIA-PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 55  ASIA-PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 56  ASIA-PACIFIC STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57  ASIA-PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58  ASIA-PACIFIC ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59  ASIA-PACIFIC NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60  ASIA-PACIFIC ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61  ASIA-PACIFIC ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62  ASIA-PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63  ASIA-PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64  ASIA-PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65  ASIA-PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66  ASIA-PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67  ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68  ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 69  ASIA-PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 70  ASIA-PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 71  ASIA-PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 72  ASIA-PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 73  ASIA-PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 74  ASIA-PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 75  ASIA-PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 76  ASIA-PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 77  CHINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 78  CHINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 79  CHINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 80  CHINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 81  CHINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82  CHINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83  CHINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84  CHINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85  CHINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86  CHINA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87  CHINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88  CHINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89  CHINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90  CHINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91  CHINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92  CHINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93  CHINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 94  CHINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 95  CHINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 96  CHINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 97  CHINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 98  CHINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 99  CHINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 100  CHINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101  CHINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102  CHINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103  JAPAN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 104  JAPAN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 105  JAPAN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 106  JAPAN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107  JAPAN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108  JAPAN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109  JAPAN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110  JAPAN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111  JAPAN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112  JAPAN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113  JAPAN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114  JAPAN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115  JAPAN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116  JAPAN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117  JAPAN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118  JAPAN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 119  JAPAN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 120  JAPAN IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 121  JAPAN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122  JAPAN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123  JAPAN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 124  JAPAN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 125  JAPAN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 126  JAPAN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 127  JAPAN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 128  JAPAN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 129  INDIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 130  INDIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 131  INDIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 132  INDIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133  INDIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134  INDIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135  INDIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136  INDIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137  INDIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138  INDIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139  INDIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140  INDIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141  INDIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142  INDIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143  INDIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 144  INDIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 145  INDIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 146  INDIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 147  INDIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 148  INDIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 149  INDIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 150  INDIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 151  INDIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 152  INDIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 153  INDIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 154  INDIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155  SOUTH KOREA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 156  SOUTH KOREA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 157  SOUTH KOREA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 158  SOUTH KOREA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 159  SOUTH KOREA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160  SOUTH KOREA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161  SOUTH KOREA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162  SOUTH KOREA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163  SOUTH KOREA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164  SOUTH KOREA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165  SOUTH KOREA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166  SOUTH KOREA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167  SOUTH KOREA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168  SOUTH KOREA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 169  SOUTH KOREA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 170  SOUTH KOREA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 171  SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 172  SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 173  SOUTH KOREA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 174  SOUTH KOREA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 175  SOUTH KOREA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176  SOUTH KOREA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 177  SOUTH KOREA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 178  SOUTH KOREA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 179  SOUTH KOREA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 180  SOUTH KOREA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 181  AUSTRALIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 182  AUSTRALIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 183  AUSTRALIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 184  AUSTRALIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 185  AUSTRALIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186  AUSTRALIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187  AUSTRALIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188  AUSTRALIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189  AUSTRALIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190  AUSTRALIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191  AUSTRALIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192  AUSTRALIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193  AUSTRALIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 194  AUSTRALIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 195  AUSTRALIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 196  AUSTRALIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 197  AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 198  AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 199  AUSTRALIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 200  AUSTRALIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 201  AUSTRALIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 202  AUSTRALIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 203  AUSTRALIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 204  AUSTRALIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 205  AUSTRALIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 206  AUSTRALIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 207  SINGAPORE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 208  SINGAPORE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 209  SINGAPORE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 210  SINGAPORE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 211  SINGAPORE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212  SINGAPORE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213  SINGAPORE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214  SINGAPORE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215  SINGAPORE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216  SINGAPORE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217  SINGAPORE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218  SINGAPORE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 219  SINGAPORE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 220  SINGAPORE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 221  SINGAPORE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 222  SINGAPORE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 223  SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 224  SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 225  SINGAPORE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 226  SINGAPORE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 227  SINGAPORE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 228  SINGAPORE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 229  SINGAPORE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 230  SINGAPORE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 231  SINGAPORE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 232  SINGAPORE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 233  THAILAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 234  THAILAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 235  THAILAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 236  THAILAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 237  THAILAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 238  THAILAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 239  THAILAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 240  THAILAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 241  THAILAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 242  THAILAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 243  THAILAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 244  THAILAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 245  THAILAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 246  THAILAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 247  THAILAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 248  THAILAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 249  THAILAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 250  THAILAND IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 251  THAILAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 252  THAILAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253  THAILAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 254  THAILAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 255  THAILAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 256  THAILAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 257  THAILAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 258  THAILAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 259  MALAYSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 260  MALAYSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 261  MALAYSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 262  MALAYSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 263  MALAYSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 264  MALAYSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 265  MALAYSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 266  MALAYSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 267  MALAYSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 268  MALAYSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 269  MALAYSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 270  MALAYSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 271  MALAYSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 272  MALAYSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 273  MALAYSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 274  MALAYSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 275  MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 276  MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 277  MALAYSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 278  MALAYSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 279  MALAYSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 280  MALAYSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 281  MALAYSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 282  MALAYSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 283  MALAYSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 284  MALAYSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 285  INDONESIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 286  INDONESIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 287  INDONESIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 288  INDONESIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 289  INDONESIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 290  INDONESIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 291  INDONESIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 292  INDONESIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 293  INDONESIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 294  INDONESIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 295  INDONESIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 296  INDONESIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 297  INDONESIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 298  INDONESIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 299  INDONESIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 300  INDONESIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 301  INDONESIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 302  INDONESIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 303  INDONESIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 304  INDONESIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 305  INDONESIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 306  INDONESIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 307  INDONESIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 308  INDONESIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 309  INDONESIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 310  INDONESIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 311  PHILIPPINES ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 312  PHILIPPINES SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 313  PHILIPPINES ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 314  PHILIPPINES TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 315  PHILIPPINES PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 316  PHILIPPINES STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 317  PHILIPPINES GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 318  PHILIPPINES ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 319  PHILIPPINES NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 320  PHILIPPINES ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 321  PHILIPPINES ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 322  PHILIPPINES ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 323  PHILIPPINES SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 324  PHILIPPINES LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 325  PHILIPPINES SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 326  PHILIPPINES DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 327  PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 328  PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 329  PHILIPPINES SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 330  PHILIPPINES LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 331  PHILIPPINES ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 332  PHILIPPINES ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 333  PHILIPPINES ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 334  PHILIPPINES ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 335  PHILIPPINES ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 336  PHILIPPINES RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 337  VIETNAM ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 338  VIETNAM SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 339  VIETNAM ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 340  VIETNAM TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 341  VIETNAM PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 342  VIETNAM STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 343  VIETNAM GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 344  VIETNAM ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 345  VIETNAM NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 346  VIETNAM ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 347  VIETNAM ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 348  VIETNAM ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 349  VIETNAM SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 350  VIETNAM LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 351  VIETNAM SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 352  VIETNAM DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 353  VIETNAM IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 354  VIETNAM IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 355  VIETNAM SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 356  VIETNAM LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 357  VIETNAM ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 358  VIETNAM ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 359  VIETNAM ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 360  VIETNAM ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 361  VIETNAM ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 362  VIETNAM RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 363  RESTF OF ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

그림 목록

FIGURE 1  ASIA PACIFIC ATAXIA MARKET: SEGMENTATION

FIGURE 2  ASIA PACIFIC ATAXIA MARKET: DATA TRIANGULATION

FIGURE 3  ASIA PACIFIC ATAXIA MARKET: DROC ANALYSIS

FIGURE 4  ASIA PACIFIC ATAXIA MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5  ASIA PACIFIC ATAXIA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6  ASIA PACIFIC ATAXIA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7  ASIA PACIFIC ATAXIA MARKET: DBMR MARKET POSITION GRID

FIGURE 8  ASIA PACIFIC ATAXIA MARKET: END USER COVERAGE GRID

FIGURE 9  ASIA PACIFIC ATAXIA MARKET: VENDOR SHARE ANALYSIS

FIGURE 10  ASIA PACIFIC ATAXIA MARKET: SEGMENTATION

FIGURE 11  RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE ASIA PACIFIC ATAXIA MARKET IN THE FORECAST PERIOD

FIGURE 12  SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ATAXIA MARKET IN 2022 & 2029

FIGURE 13  NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14  DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ATAXIA MARKET

FIGURE 15  ASIA PACIFIC ATAXIA MARKET: BY TYPE, 2021

FIGURE 16  ASIA PACIFIC ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)

FIGURE 17  ASIA PACIFIC ATAXIA MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 18  ASIA PACIFIC ATAXIA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, 2021

FIGURE 20  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)

FIGURE 21  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 22  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 23  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, 2021

FIGURE 24  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)

FIGURE 25  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 26  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 27  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 28  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)

FIGURE 29  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 30  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 31  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, 2021

FIGURE 32  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)

FIGURE 33  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 34  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 35  ASIA PACIFIC ATAXIA MARKET: BY END USER, 2021

FIGURE 36  ASIA PACIFIC ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)

FIGURE 37  ASIA PACIFIC ATAXIA MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38  ASIA PACIFIC ATAXIA MARKET: BY END USER, LIFELINE CURVE

FIGURE 39  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)

FIGURE 41  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 42  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43  ASIA-PACIFIC ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 44  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 45  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47  ASIA-PACIFIC ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 48  ASIA PACIFIC ATAXIA MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

Asia-Pacific Ataxia Market is growing with a CAGR of 7.8% by 2029.
Asia-Pacific Ataxia Market is expected to reach USD 7,734.86 thousand by 2029.
The difficulty in diagnosing the disease and lack of genetic testing facilities in some of the developing countries will impede the growth rate of the ataxia market.
The major players operating in the Asia-Pacific ataxia market are Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Reata Pharmaceuticals, Inc., Biohaven Pharmaceuticals, among others.